EP
UTHR icon

Essential Partners’s United Therapeutics UTHR Stock Holding History

Essential Partners’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$157K Sell
289
-44
-13% -$24.8K 0.07% 303
2026
Q1 		$197K Sell
333
-1,247
-79% -$621K 0.07% 296
2025
Q4 		$770K Buy
1,580
+1,388
+723% +$646K 0.24% 120
2025
Q3 		$80.5K Sell
192
-2
-1% -$673 0.03% 483
2025
Q2 		$55.7K Buy
+194
New +$58K 0.02% 450

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Essential Partners's UTHR Position: Q2 2026 in Review

Essential Partners reduced its United Therapeutics (UTHR) stake by 13% in Q2 2026, selling an estimated $24.8K and leaving 289 shares worth $157K. The position accounts for 0.07% of the portfolio, ranked #303.

Essential Partners first reported a position in UTHR in Q2 2025 and has held it in 5 quarters since. The position peaked at $770K in Q4 2025. 878 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Essential Partners held 289 shares of United Therapeutics worth $157K as of Q2 2026.
  • Essential Partners sold 44 United Therapeutics shares in Q2 2026, an estimated $24.8K.
  • United Therapeutics made up 0.07% of Essential Partners's portfolio in Q2 2026, its #303 holding.
  • Essential Partners first reported a position in United Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Essential Partners's United Therapeutics position peaked at $770K in Q4 2025.
  • 878 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.